TargetMol

AT7519

Product Code:
 
TAR-T6205
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6205-5mg5mg£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6205-1mL1 mL * 10 mM (in DMSO)£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6205-10mg10mg£134.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6205-25mg25mg£161.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6205-50mg50mg£206.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6205-100mg100mg£251.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.
CAS:
844442-38-2
Formula:
C16H17Cl2N5O2
Molecular Weight:
382.25
Pathway:
PI3K/Akt/mTOR signaling; Apoptosis; Cell Cycle/Checkpoint; Stem Cells
Purity:
0.9967
SMILES:
Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1
Target:
Apoptosis; GSK-3; CDK

References

Zhao W, Zhang L, Zhang Y, et al.The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest.Cell Death & Disease.2023, 14(1): 11. Kazi A, Chen L, Xiang S, et al. Global Phosphoproteomics reveal CDK suppression as a vulnerability to KRAS addiction in Pancreatic Cancer. Clinical Cancer Research. 2021 Jul 15;27(14):4012-4024. doi: 10.1158/1078-0432.CCR-20-4781. Epub 2021 Apr 20. Kazi A, Chen L, Xiang S, et al. Global Phosphoproteomics reveal CDK suppression as a vulnerability to KRAS addiction in Pancreatic Cancer[J]. Clinical Cancer Research. 2021 Santo L, et al. Oncogene, 2010, 29(16), 2325-2336. Squires MS, et al. Mol Cancer Ther, 2009, 8(2), 324-332.